Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07321873 | A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | PHASE2 | RECRUITING | 240 | — | — | Jan 15, 2026 | Aug 2, 2027 | Jun 5, 2026 | 68 | United States, China +6 |
The ACR 50 responders are participants with an improvement of greater than or equal to (\>=) 50 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale \[VAS\], patient's global assessment of disease activity \[arthritis, VAS\] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).
| Arm | Type | Description |
|---|---|---|
| Arm 1: Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo to JNJ-88545223, from Week 0 to Week 16. |
| Arm 2: JNJ-88545223 Dose 1 | EXPERIMENTAL | Participants will receive JNJ-88545223 Dose 1 from Week 0 to Week 16. |
| Arm 3: JNJ-88545223 Dose 2 | EXPERIMENTAL | Participants will receive JNJ-88545223 Dose 2 from Week 0 to Week 16. |
| Arm 4: JNJ-88545223 Dose 3 | EXPERIMENTAL | Participants will receive JNJ-88545223 Dose 3 from Week 0 to Week 16. |
| Name | Type | Description |
|---|---|---|
| JNJ-88545223 | DRUG | JNJ-88545223 will be administered. |
| Placebo | DRUG | Placebo will be administered. |
Inclusion Criteria: * Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening * Have active PsA as defined by: (a) At least 3 swollen joints and at least ...